Analysis of 24-month interim data from the pivotal CYPRESS clinical trial has shown spectacles that use SightGlass Vision Diffusion Optics Technology significantly reduce both axial length (mean absolute reduction = 0.27 mm) and cycloplegic SER progression (mean absolute reduction = 0.77 D) in six- and seven-year-old children versus the control.
The focus on age is of particular interest to eye care professionals and researchers, as myopia progresses fastest in the youngest children.1,2 Since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health.
Study investigators enrolled, randomised, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada – a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrolment, subjects were six to 10-years-old having myopia between -0.75D and -4.50D, with nearly a third being six or seven-years-old. With a mean age of 8.1 years at screening, the entire CYPRESS cohort is younger than children in many other well-known myopia management studies across various interventions. The trial is now in its third year.
Spectacle lenses using patent protected SightGlass Vision Diffusion Optics Technology incorporate thousands of microdots that softly scatter light to reduce contrast on the retina – a method intended to reduce myopia progression in children.
The findings3 were presented for the first time at the 2022 Dutch Contact Lens Congress in June 2022.
References
- Hyman L, et al. Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial. Archives of Ophthalmology. 2005;123(7):977 987.
- Verkicharla PK, Kammari P, Das AV. Myopia progression varies with age and severity of myopia. PLOS ONE. 2020;15(11):e0241759.
- Rappon J, Neitz J, Neitz M, Chalberg T. Two Year Effectiveness of a Novel Myopia Management Spectacle Lens in Young Myopes.